A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Travera Inc
Nammi Therapeutics Inc
Exscientia AI Limited
Arcus Biosciences, Inc.
Sotio Biotech Inc.
GlaxoSmithKline
AstraZeneca
Merck Sharp & Dohme LLC
Hoffmann-La Roche
ViroMissile, Inc.
Tizona Therapeutics, Inc
A2 Biotherapeutics Inc.
Poseida Therapeutics, Inc.
MacroGenics
Ocellaris Pharma, Inc.
Novartis
NeoTX Therapeutics Ltd.
OncoHost Ltd.
Bolt Biotherapeutics, Inc.
Nanobiotix
ITM Oncologics GmbH
Actym Therapeutics, Inc.
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Scancell Ltd
A2 Biotherapeutics Inc.
Exelixis
Incyte Corporation
Xencor, Inc.
Numab Therapeutics AG
A2 Biotherapeutics Inc.
Medicenna Therapeutics, Inc.
NextPoint Therapeutics, Inc.
OncoC4, Inc.
Merus B.V.
Kymab Limited
Cofactor Genomics, Inc.
Taproot Health
Novartis
Travera Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
Simcha IL-18, Inc.
AstraZeneca
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Novartis
NGM Biopharmaceuticals, Inc
Xencor, Inc.